In this article
The market share of India’s most popular weight‑loss drugmaker, Eli Lilly
, slipped in March, while rival Novo Nordisk held steady even as Indian generic drugmakers flooded the market with lower‑priced copies.
Eli Lilly’s Indian market share in the GLP‑1 category of weight‑loss drugs fell to 56% in March from 61% a month earlier, according to data from industry intelligence provider Pharmarack. Novo Nordisk’s market share remained steady at 25%.
India is a critical market, with around 100 million people living with diabetes and nearly a quarter of the population classified as overweight or obese. The country is also known as the “world’s pharmacy,” with its well-developed generic drugs industry supplying around 20% of global generic medicines.
